AN

Aparna Nandavaram

Active Director Director DIN 09666363
DIN 09666363 First appointment Jul 2022 Primary industry Research & Development
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Aparna Nandavaram

Data last updated:

Aparna Nandavaram is a Director at Veles Therapeutics Private Limited (since 2022). The company operates in Research & Development.

DIN 09666363
Primary Designation Director
Industry Research & Development
First Appointment 07 Jul 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Veles Therapeutics Private Limited U73100KA2022PTC163522
Director07 Jul 20222022Active

Board colleagues of Aparna Nandavaram

NameDINCompanyDesignation
Durga Devi Charllapally09604223Veles Therapeutics Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Veles Therapeutics Private Limited
Premium access

Shareholding and investment profile for Aparna Nandavaram

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aparna Nandavaram

Aparna Nandavaram currently holds 1 directorship: Veles Therapeutics Private Limited (Director, since 07 Jul 2022).

Aparna Nandavaram was first appointed on 07 Jul 2022 as Director at Veles Therapeutics Private Limited.

The current boards of Aparna Nandavaram's companies include Durga Devi Charllapally (Veles Therapeutics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available